MAPK1 and cancer: However, when the patients are treated with ERK pathway-targeted therapeutics, PHLDA1/2 levels are downregulated in cancer cells, leading to the unwanted enhancement of AKT activity and associated cell survival, and thereby to resistance to the anti-cancer agents (Supplementary Fig. 9h).